New PMC Report Shows FDA Advancing a New Era of Personalized, Patient-Centered CareWashington, DC, May 14, 2026 (GLOBE NEWSWIRE) -- The Personalized Medicine Coalition released a new report documenting the U.S. Food and Drug Administration’s continued progress in advancing personalized medicine in 2025, including the approval of 16 new personalized medicines representing approximately 36% of all newly approved therapeutic molecular entities. The report also highlights the approval of five new gene- and cell-based therapies and significant advances in diagnostics, artificial intelligence, and rare disease innovation.
PMC’s FDA Report Shows Continued Progress for Personalized MedicineThe annual analysis documented approvals of 18 new personalized medicines in 2024, important regulatory milestones and establishment of the Center for Drug Evaluation and Research AI Council
Personalized Medicine Coalition Announces Amy Nicole Nayar as Next President and CEOVisionary Leader Brings Multifaceted Health Care Expertise and Proven Success in Uniting Public and Private Sectors Around Shared Goals
